
|Articles|April 26, 2004
Weisenfeld Award winner highlights the success behind retinoblasma treatment, survival rate
One of the few success stories in pediatric oncology, retinoblastomahas ridden scientific and therapeutic advances to a near-100% survival,a 180-degree turnabout from a century ago, said the 2004 recipient of MildredWeisenfeld Award for Excellence in Ophthalmology.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
3
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
4
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
5















































.png)


